A phase I pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2021 Primary endpoint ( To determine the absorption and PK characteristics of an oral capsule formulation of ATO (intrasubject comparison of peak serum level and AUC0-24)) has been met.
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
13 May 2021 According to a Phebra media release, final results from this trial will be presented at the virtual European Hematology Association (EHA) 2021 Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com